Skip to main content

A Simple Technique to Establish a Long-Term Adenovirus Mediated Gene Transfer to the Heart of Newborn Mice

Buy Article:

$55.00 plus tax (Refund Policy)

Previous studies using different techniques have shown that adenoviral-mediated gene transfer to different tissues, including the kidney, is more efficient in neonatal mice. In this study, we report a simple technique that allows an efficient and long term expression of β-galactosidase (β-gal) in the heart of newborn mice. Newborn and adult C57BL6/J mice were subjected to a single retro-orbital venous plexus injection of recombinant adenoviral vectors (rAd) (2 x 109 particles/ g body weight) carrying the lac Z gene. Seven days after the injection, positive β-gal staining was systematically observed in the heart, lung, intestine, liver, kidney and spleen of newborn mice. However, only the heart showed persistent expression of β-gal one year after the initial injection. In contrast, adult mice showed only significant but transient β- gal expression mainly in the liver. In summary, we have found that a single retro-orbital intravenous injection can be used to establish a long-term adenoviral-mediated gene transfer to cardiac cells of newborn mice.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Recombinant adenoviral vector; cardiomyocytes; heart; long term gene transfer; newborn mouse

Document Type: Research Article

Publication date: 2009-06-01

More about this publication?
  • Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more